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Apathy and impulsivity in frontotemporal lobar
degeneration syndromes
Claire J. Lansdall,1 Ian T. S. Coyle-Gilchrist,1 P. Simon Jones,1 Patricia Va´zquez Rodrı´guez,1
Alicia Wilcox,1 Eileen Wehmann,1,2 Katrina M. Dick,3 Trevor W. Robbins4,5 and
James B. Rowe1,4,6
Apathy and impulsivity are common and disabling consequences of frontotemporal lobar degeneration. They cause substantial
carer distress, but their aetiology remains elusive. There are critical limitations to previous studies in this area including (i) the
assessment of either apathy or impulsivity alone, despite their frequent co-existence; (ii) the assessment of behavioural changes
within single diagnostic groups; and (iii) the use of limited sets of tasks or questions that relate to just one aspect of these
multifactorial constructs. We proposed an alternative, dimensional approach that spans behavioural and language variants
of frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome. This accommodates the commonalities
of apathy and impulsivity across disorders and reveals their cognitive and anatomical bases. The ability to measure the components
of apathy and impulsivity and their associated neural correlates across diagnostic groups would provide better novel targets for
pharmacological manipulations, and facilitate new treatment strategies and strengthen translational models. We therefore sought to
determine the neurocognitive components of apathy and impulsivity in frontotemporal lobar degeneration syndromes. The fre-
quency and characteristics of apathy and impulsivity were determined by neuropsychological and behavioural assessments in 149
patients and 50 controls from the PIck’s disease and Progressive supranuclear palsy Prevalence and INcidence study (PiPPIN). We
derived dimensions of apathy and impulsivity using principal component analysis and employed these in volumetric analyses of
grey and white matter in a subset of 70 patients (progressive supranuclear palsy, n = 22; corticobasal syndrome, n = 13; behav-
ioural variant, n = 14; primary progressive aphasias, n = 21) and 27 control subjects. Apathy and impulsivity were present across
diagnostic groups, despite being criteria for behavioural variant frontotemporal dementia alone. Measures of apathy and impul-
sivity frequently loaded onto the same components reﬂecting their overlapping relationship. However, measures from objective
tasks, patient-rated questionnaires and carer-rated questionnaires loaded onto separate components and revealed distinct neuro-
biology. Corticospinal tracts correlated with patients’ self-ratings. In contrast, carer ratings correlated with atrophy in established
networks for goal-directed behaviour, social cognition, motor control and vegetative functions, including frontostriatal circuits,
orbital and temporal polar cortex, and the brainstem. Components reﬂecting response inhibition deﬁcits correlated with focal
frontal cortical atrophy. The dimensional approach to complex behavioural changes arising from frontotemporal lobar degenera-
tion provides new insights into apathy and impulsivity, and the need for a joint therapeutic strategy against them. The separation
of objective tests from subjective questionnaires, and patient from carer ratings, has important implications for clinical trial design.
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Introduction
The clinical syndromes associated with frontotemporal
lobar degeneration (FTLD) are clinically, genetically and
pathologically heterogeneous (Josephs, 2008a; Piguet
et al., 2011; Rohrer and Warren, 2011). The syndromes
include behavioural variant and language variants of fron-
totemporal dementia (FTD), progressive supranuclear palsy
(PSP) and the corticobasal syndrome (CBS). Apathy and
impulsivity are common and distressing features of these
disorders (Zamboni et al., 2008; Piguet et al., 2011;
Leroi et al., 2012). They are diagnostic criteria for behav-
ioural variant frontotemporal dementia (bvFTD)
(Rascovsky et al., 2011), and supportive criteria for PSP
(Litvan et al., 1996), but occur frequently across the full
spectrum of disorders associated with FTLD (Mendez et al.,
2008; Burrell et al., 2014; Coyle-gilchrist et al., 2016).
Apathy and impulsivity may be concurrent in an individual
patient (Kertesz et al., 2005; Chow et al., 2009), suggesting
that they are not simply opposite ends of a behavioural
spectrum (Sinha et al., 2013).
Both apathy and impulsivity are multifaceted constructs
(Levy and Dubois, 2006; Dalley et al., 2011; Nombela
et al., 2014), with multiple contributory factors. These fac-
tors may be expressed in terms of brain network pathology
(Everitt and Robbins, 2005; Zamboni et al., 2008; Eslinger
et al., 2013; Sinha et al., 2013; Nombela et al., 2014; Ye
et al., 2014, 2016), or the cognitive processes of motivation,
reward and decision-making (Levy and Dubois, 2006; Adam
et al., 2012; Ahearn et al., 2012; Zhang et al., 2016), and
pharmacology (Cools et al., 2005; Eagle et al., 2008; Dalley
et al., 2011). For example, apathy has been linked to deﬁcits
in motivational circuitry, speciﬁcally orbitofrontal connec-
tions to the ventral striatum (Everitt and Robbins, 2005;
Levy and Dubois, 2006), and dopamine (Adam et al.,
2013; Sinha et al., 2013). Impulsivity has also been linked
to disruptions of dopaminergic, noradrenergic and serotoner-
gic regulation of frontostriatal circuits (Dalley et al., 2011;
Ye et al., 2014, 2015; Hughes et al., 2015; Zhang et al.,
2016). The presence of apathy and impulsivity across differ-
ent clinical diagnoses, and the evidence for their distinct
components, creates a major challenge for the development
of new therapeutic strategies.
To elucidate the physiological, pharmacological and gen-
etic causes of apathy and impulsivity, and to design
appropriately stratiﬁed and powered clinical trials of can-
didate treatments, three critical items are needed. First, a
clear deﬁnition of the cognitive and behavioural compo-
nents of apathy and impulsivity, from which to develop
robust and targeted assessment tools. Second, knowledge
of how these different components are represented trans-
diagnostically, across disorders associated with FTLD.
Despite recent progress in clinical, pathological and genetic
fractionation of these disorders (Gorno-Tempini et al.,
2011; Rascovsky et al., 2011; Armstrong et al., 2013),
phenotypic boundaries are not always distinct. Third, one
requires evidence for the neural basis of the components,
both to generate surrogate markers in experimental medi-
cines studies and to validate preclinical models of behav-
ioural disorders.
Previous studies have often focused on apathy or impul-
sivity in isolation, employing a limited range of measures or
summary metrics. However, apathy and impulsivity are co-
existent multifactorial constructs, with each factor likely re-
ﬂecting different anatomical and/or pharmacological under-
pinnings. A dimensional approach, such as a principal
component analysis on a broad range of assessment types,
would provide greater power to capture all aspects of apathy
and impulsivity. We aimed to assess apathy and impulsivity
from the patient and carer perspective, as measured by ques-
tionnaires of the type commonly used in clinical trials,
enabling assessment of potential discrepancies between
carer and patient ratings. We also used objective neuropsy-
chological and behavioural tests to bridge between preclin-
ical and clinical studies, supporting translational models.
Taken together, these assessment tools capture the major
domains of apathy and its principal confounds, including
motivation, anhedonia, depression/mood and akinesia and
the major domains of impulsivity, including reward sensitiv-
ity, response inhibition and information sampling.
It has also been common to study apathy or impulsivity
in single diagnostic groups. However, the soft boundaries
between clinical phenotypes and the overlap of clinical fea-
tures as disease progresses (Kertesz et al., 2005; Coyle-
gilchrist et al., 2016) calls for an alternative approach,
accommodating commonalities across disorders. Such a
transdiagnostic approach remains sensitive to the hetero-
geneity both within and across groups. For example, two
patients with bvFTD can meet diagnostic criteria without
sharing a single core clinical feature (Rascovsky et al.,
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2011). In contrast, patients with the semantic variant of
progressive aphasia (svPPA) meet different diagnostic cri-
teria to bvFTD, but they often develop similar behavioural
changes later in their disease course. Examination of the
commonalities across the full spectrum of clinical pheno-
types associated with FTLD therefore provides increased
power and facilitates the dissection of major components
of apathy and impulsivity.
This study drew on a dimensional approach. It was
inspired by the ‘Research Domain Criteria’ framework for
psychiatric disorders (Kozak and Cuthbert, 2016), which
aims to develop new ways of classifying disorders based
on dimensions of observable behaviour and neurobiological
measures; embracing the overlap between clinical features
in contrast to a categorical approach to diagnosis
(Cuthbert, 2014). It can provide a mechanistic model to
bridge between different levels of analysis of disease patho-
genesis and their causal relationships. We implemented a
data-driven analysis to identify the components (as dimen-
sions) of apathy and impulsivity empirically, which we then
interpret in terms of motivation, reward sensitivity, motor
and cognitive control. Our speciﬁc hypotheses were that (i)
apathy and impulsivity are multifactorial constructs, but
with common and overlapping features; (ii) subjective and
objective measures relate to the same components; and (iii)
distinct frontostriatal, frontotemporal and brainstem cir-
cuits support the components of apathy and impulsivity.
Materials and methods
Context and participants
The Pick’s disease and Progressive supranuclear palsy
Prevalence and INcidence (PiPPIN) study, provided the ideal
arena to test our hypotheses, combining neuropsychological,
behavioural and MRI assessments. This epidemiological
study of FTD, CBS and PSP patients was carried out in the
UK (Coyle-gilchrist et al., 2016). Diagnoses were based on
current criteria for bvFTD (Rascovsky et al., 2011), primary
progressive aphasia (PPA) syndromes (Gorno-Tempini et al.,
2011), PSP (Bensimon et al., 2009) and CBS (Armstrong
et al., 2013), following clinical interview, physical examin-
ation, relevant exclusionary tests and brain imaging. The
PPAs were subtyped (Gorno-Tempini et al., 2011) into the
non-ﬂuent agrammatic variant (nvPPA), the semantic variant
(svPPA), and a third group that included logopenic variant
(lvPPA) and mixed aphasia (PPA as the prominent syndrome
but not ﬁtting criteria for one of the three deﬁned subtypes).
We estimated the years from symptom onset, based on recall
of initial relevant symptoms. Two hundred and four patients
were identiﬁed, 167 of whom were assessed in person by a
member of the study team. Eighteen either died before neuro-
psychological assessment or were unable to undertake testing
over and above diagnostic conﬁrmation, leaving 149 patient
datasets for analysis by principal component analysis. Fifty
healthy age- and sex-matched controls were recruited from
the Medical Research Council’s Cognition and Brain Sciences
Unit volunteer panel, with no signiﬁcant neurological or psy-
chiatric history.
A subset of 70 patients (PSP, n = 22; CBS, n = 13; bvFTD,
n = 14; nvPPA, n = 12; svPPA, n = 4; other PPA, n = 5) and 27
control subjects underwent MRI. The imaging subset was repre-
sentative of the cohort, with no signiﬁcant differences between
the imaging subset (n = 70) and the non-imaged patients (n = 79)
in terms of demographics, disease characteristics and the major
outcome variables included in the analysis (Supplementary Table
1). Most patients underwent MRI on the same day as cognitive
assessment (median and mode = 0 days).
Participants were tested while on their usual medication. Forty
per cent of patients were taking antidepressant medications (for
either affective or behavioural indications), 4% were taking
antipsychotic medication, and 29% were taking dopaminergic
medication (for movement disorder). Thirty-seven per cent were
taking other medications that may act on the CNS including
benzodiazepines (for anxiolysis, sedation or myoclonus), antie-
pileptic medication, analgesics (opioid, gabapentin, pregabalin),
including one case on cholinesterase inhibitors.
The study was approved by the Cambridge 2 Research Ethics
Committee. Informed consent was obtained at each study visit,
with a ‘personal consultee’ process used for participants who
lacked mental capacity, in accordance with UK law.
Neuropsychological, behavioural and
imaging assessment battery
In selecting our test battery, we applied the following prin-
ciples: to include clinically standard tests as well as experimen-
tal paradigms; to include questionnaires to be completed by
patients as well as by carers so as to provide complementary
perspectives; to include both subjective symptom-based ques-
tionnaires and objective neuropsychological tests for both pa-
tients and controls; to measure depression symptoms and
akinesia as well as direct tests of cognitive and behavioural
aspects of apathy and impulsivity; to prioritize untimed tests
in view of likely akinesia in many participants; and use only
tasks that have been published and used with independent
cohorts. Details of the questionnaires and behavioural
tasks used to evaluate apathy and impulsivity are listed in
Table 1, while we summarize below the less common assess-
ment tools (see Supplementary material for full details).
The assessment of cognitive impairment and disease severity
included the Addenbrooke’s Cognitive Examination-Revised
(ACE-R), Mini-Mental State Examination (MMSE),
Frontotemporal Dementia Rating Scale (FRS), PSP Rating
scale (PSPRS) and Frontal Assessment Battery (FAB).
The Cambridge Neuropsychological Test Automated Battery
(CANTAB, Cambridge Cognition, UK) was used for the Stop-
signal Task (Aron et al., 2003), Information Sampling Task
(Lawrence et al., 2009) and the modiﬁed version of the
Cambridge Gambling Task for clinical cohorts
(Supplementary material). However, the gambling task was
removed after 37 participants due to ﬂoor effects and difﬁcult
task engagement by patients. Patients were able to perform the
Cued Reinforcement Reaction Time task, which provides an
alternative measure of reward responsiveness (Cools et al.,
2005). Prior to each trial, participants observed a coloured
rectangle signalling the probability of reward following a cor-
rect response (20% versus 80% probability). Participants then
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Table 1 Assessment battery
Measurement Type Rater Description Outcome variables
entered for local PCA
Summary of scores
or local PCA loadings
Apathy Evaluation
Scale (AES)
Q P, I, C 18 items assessing emotional, behav-
ioural and cognitive constructs of
apathy
Cognition
Emotion
Behaviour
AES 1: patient ratings
AES 2: mainly carer and
clinician
Barratt
Impulsiveness
Scale (BIS)
Q P 30 item self-report questionnaire.
Reflecting the multifactorial struc-
ture of impulsivity.
Attention
Motor
Self control
Cognitive complexity
Perseverance
Cognitive instability
BIS 1: Attention, self con-
trol, cognitive com
plexity, perseverance.
BIS 2: Motor and cognitive
instability
Behavioural
Inhibitory System
Behavioural
Approach System
(BIS/BAS)
Q P 24 item self-report questionnaire
based on Grey’s biopsychological
theory of personality
BIS subscore
BAS drive
BAS fun-seeking
BAS reward Responsiveness
BIS/BAS 1: BAS subscores
BIS/BAS 2: BIS subscore
Cambridge
Behavioural
Inventory (CBI-R)
Q C 45 item questionnaire, developed to
evaluate behavioural changes asso-
ciated with dementia.
Memory/orientation
Everyday skills; self-care
Abnormal behaviour; mood; Beliefs;
Eating habits; sleep; Stereotypical be-
haviour; Motivation
CBI 1: Challenging
behaviours
CBI 2: Everyday skills and
self-care
Motivation and
Energy Inventory
(MEI)
Q P 27 item questionnaire developed to
evaluate reductions in motivation
and energy in depression research,
although commonly used in other
disease areas.
Total score Total score
Snaith-Hamilton
Pleasure Scale
(SHAPS)
Q P 14 item questionnaire targeting he-
donic capacity (anhedonia).
Total score Total score
Beck Depression
Inventory (BDI)
Q P 21 item questionnaire, widely used to
measure the severity of depression.
Total score Total score
Kirby Q P Serial forced choice questionnaire to
quantify the tendency to prefer
small immediate rewards over
larger delayed rewards
Kdiff calculated: Difference in delayed
discounting (K) from small to large
delayed rewards (Klarge-Ksmall),
termed Kdiff.
Kdiff single score
Information
Sampling Task (IST)
B P Reflection impulsivity task, based on
the information and time used by
participants before making a two-
choice probabilistic decision.
Proportion of correct trials
Box latency; colour latency;
Total correct; sampling error
IST 1: Proportion of cor-
rect trials, boxes
opened, total correct
IST 2: Box and colour
latency
IST 3: Sampling error, -
boxes opened
Cued reinforce-
ment reaction time
(CRRT)
B P Reward sensitivity task measuring mo-
tivationally driven behaviour.
Speeding first half of trials
Speeding second half of trials
Difference in speeding from FH-SH
Total errors
CRRT 1: Difference
speeding, Errors, -
Speeding FH
CRRT 2: Speeding SH,
Difference speeding
Stop signal task
(SST)
B P Action cancellation task. SSRT
Median reaction time on correct GO
trials
Proportion of successful stops
SST 1: all variables entered
Motor NoGo B P Inhibition of a prepotent
motor response.
Calculated Dprime: lower values reflect
decreased ‘hits’ (correct on Go trials)
and increased false alarms (Go on
NoGo trials: commission errors).
Dprime
Saccade NoGo S P Inhibition of cued saccade Calculated Dprime: lower values reflect
decreased ‘hits’ (correct on Go trials)
and increased false alarms (Go on
NoGo trials: commission errors).
Dprime
Cambridge
Gambling Task
(CGT)
B P Visual gambling task to measure risk-
taking and decision making
behaviour.
N/A N/A
Test type included questionnaires (Q), behavioural tasks (B) and saccades (S). Tests were completed by the patient (P), carer (C) or investigator (I).
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identiﬁed the ‘odd-one-out’ of three circles to receive feedback:
100 points for a fast correct, 1 point for a slow correct re-
sponse and 0 points for an incorrect response. This task in-
duces a ‘reinforcement-related speeding’ effect, making faster
responses with increased probability of reward. Forty practice
trials without feedback were used to titrate reaction time
thresholds to individual differences in cognitive speed.
The saccadic NoGo task (Zhang et al., 2016) used direct
infrared oculography from a head-mounted saccodometer
(OberConsulting). Each session included 300 trials, following
10 calibration trials. Participants ﬁxated centrally (red/green
dots) on a screen at 1.5m distance. After 300ms, one of
the central cues was removed and a red dot was presented
at 10 or + 10 degree horizontal displacement (randomized,
50:50). In 50% of trials, the green central cue remained and
participants responded by a saccade to lateral target (Go
trials). In NoGo trials, the red central cue remained and par-
ticipants refrained from making a saccade. Data were analysed
using LatencyMeter (Ober Consulting Version 6.5), with auto-
matic trials validation to eliminate abnormal saccades based
on the position and velocity proﬁle of each trace. The motor
NoGo task was analogous to the saccadic task but used a
joystick operated by the right hand (Supplementary material).
Outcome measures for NoGo tasks included d-prime for per-
formance accuracy, commission and omission error rates and
reaction times.
MRI was performed at the Wolfson Brain Imaging Centre,
using a TIM-Trio 3T scanner (Siemens). T1-weighted magnet-
ization-prepared rapid acquisition gradient-echo (MPRAGE)
images were acquired with a repetition time = 2300ms, echo
time = 2.86ms, matrix = 192  192, in-plane resolution of
1.25  1.25mm, 144 slices of 1.25mm thickness, inversion
time = 900ms and ﬂip angle = 9. Signiﬁcant effects were iden-
tiﬁed using cluster-level statistics. An uncorrected height
threshold of P50.005 was used to identify voxels and spatial
extent was corrected for multiple comparisons at P50.05.
Preprocessing used diffeomorphic anatomical registration
using exponentiated Lie algebra (DARTEL) in SPM12 follow-
ing brain extraction. The T1 images were segmented using de-
fault settings to output the DARTEL import images for grey
and white matter. Then a study-speciﬁc template was created
using ﬁve age-matched participants from each of the seven
diagnostic groups (to reduce group bias). The remaining sub-
jects’ data were warped to the template. Next, the grey and
white matter template segments were afﬁne-transformed to
MNI space. The afﬁne template transformation was applied
to the maps of the individual participants together with
smoothing by an 8mm isotropic full-width at half-maximum
Gaussian kernel. The total intracranial volume was calculated
using Tissue Volumes function in SPM12, and study-speciﬁc
masks created from voxels with a value of 40.1 in 480%
(Barnes et al., 2010) of the images.
Statistical analysis
The analyses aimed to (i) identify the underlying components
of apathy and impulsivity; and (ii) determine their associated
neural correlates. Statistical analysis of behavioural and neuro-
psychological data used SPSS v22.0 (IBM). Demographic data
and disease characteristics, including age, gender, ACE-R total
score and FRS total score, and the principal outcome measure
for each of the eight questionnaires and four objective
behavioural tasks were also compared using two-sample
t-tests between groups (patient versus control).
Principal components analysis
Principal components analysis (PCA) identiﬁed the components
of apathy and impulsivity that best explained the data vari-
ance, reducing the dimensionality and increasing reliability by
combining data from multiple tests. PCAs were run on patient
and control data combined (n = 199, noting that there were no
major differences to the component structure if using only 149
patients’ data). The correlation matrix was used for extraction
of components. Kaiser-Meyer-Olkin and Bartlett’s test of
sphericity were used to determine the adequacy of the
sample size for PCA analysis.
We took a hierarchical approach to the PCA, since many of
the individual tasks give rise to multiple outcome measures
(Supplementary Fig. 1). First, task-speciﬁc ‘local’ PCAs using
orthogonal varimax rotation were performed separately on the
individual questionnaires and behavioural measures (Table 1).
Varimax rotation ensures orthogonality, maximizes the disper-
sion of loadings within components and facilitates interpret-
ation. Selection of components used Kaiser’s or Cattell’s
criteria, whichever was more inclusive, plus an additional cri-
terion of explaining 410% of the variance. Component load-
ings 40.50 were considered meaningful and component scores
were computed using the regression method. Second, the com-
ponents extracted from each of the local PCAs were included
in a ﬁnal PCA, which also included total scores or d-prime
from the tests that were not subject to local PCA (Table 1).
Selection of components used Kaiser’s or Cattell’s criteria,
whichever was more inclusive. Component scores were also
correlated with age, cognition (ACE-R, MMSE and FAB)
and disease severity (FRS) in SPSS v22 (IBM).
Voxel-based morphometry
Due to orthogonality of PCA components, their neural correl-
ates were identiﬁed by a general linear model, using the
smoothed normalized grey and white matter segments. The
design matrix included the eight mean centred Principal
Component Factor scores, age, gender and total intracranial
volume and an intercept. Both positive and negative contrasts
were examined from the General Linear Model for all eight
principal components. Signiﬁcant effects were identiﬁed using
cluster-level statistics (FWEc P50.05, corrected for multiple
comparisons) above a height threshold of P50.005 (uncor-
rected). The non-stationary cluster extent correction was
applied in view of the non-uniformity of the data.
Results
Behavioural results
The neuropsychological and behavioural performance by
patient and control data are presented in Tables 2 and 3
(see Supplementary Table 2 for performance by diagnostic
group). Patients and controls were matched for age and
gender. Patients had signiﬁcant cognitive deﬁcits compared
to controls in addition to signiﬁcantly higher apathy
(Apathy Evaluation Scale, AES), impulsivity (Barratt
Impulsiveness Scale, BIS), depression (Beck Depression
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Inventory, BDI) and anhedonia (Snaith-Hamilton Pleasure
Scale, SHAPS) with lower levels of motivation (Motivation
and Energy Inventory, MEI). Patients also demonstrated
signiﬁcant impairments on behavioural tasks of reﬂection
impulsivity (information sampling task), incentive
motivation (cued reinforcement), response inhibition
(limb-motor and saccade tasks) and action cancellation
(Stop-Signal task). The Behavioural Inhibition System/
Behavioural Activation System (BIS/BAS) and Kirby re-
sponses did not differentiate between patients and controls.
Patients also demonstrated cognitive and functional im-
pairment across groups compared to controls, as measured
by the ACE-R, MMSE, FRS, and FAB (Table 3). Additional
motor features were also present in some patients across
diagnostic groups, including akinesia, rigidity, dystonia,
apraxia, vertical gaze palsy, postural instability, and myo-
clonus (Table 3).
Principal component analysis
The sample size was adequate for analysis (Kaiser-Meyer-
Olkin stat = 0.743) and correlations between items were
sufﬁciently large for PCA (Bartlett’s test of spher-
icity231 = 508.013, P5 0.001). Eight components were
Table 2 Summary of patient and control characteristics
Variable Controls Patients
(all groups)
T statistic Group
difference
Demographics and cognition
Age 70.6  6.5 69.9  8.2 0.9 NS
Gender M:F 23:27 76:73 (2 = 0.6) NS
ACE-R total (max. 100) 95.6  4.4 64.7  22.6 12.7 **(*)
MMSE total (max. 30) 29.3  1.2 22.3  6.8 9.6 **(*)
FRS % score (max. 100) 92.1  10.8 37.9  26.5 18.5 **(*)
Questionnaires
Apathy Evaluation Scale (AES, max. 72):
Carer 24.2  5.7 48.1  12.4 16.7 **(*)
Patient 25.7  5.6 36.1  9.4 7.8 **(*)
Clinician 25.9  7.3 43.6  10.0 11.8 **(*)
Barratt Impulsiveness Scale (BIS, max. 120) 57.0  7.4 63.6  8.1 4.6 **(*)
Behavioural Inhibition System/Behavioural Activation System (BIS/BAS):
BIS subscore 19.9  3.4 20.6  4.5 1.0 NS
BAS drive 10.0  2.1 10.9  3.2 1.9 NS
BAS fun-seeking 10.7  2.2 11.3  3.0 1.2 NS
BAS reward responsivness 15.8  2.4 16.6  2.7 1.7 NS
Motivation and energy inventory (MEI, max. 144) 108.9  17.2 81.1  26.4 7.0 **(*)
Beck Depression Inventory (BDI, max. 63) 4.2  4.0 13.0  10.1 6.7 **(*)
Snaith-Hamilton pleasure scale (SHAPS, max. 56) 18.6  4.4 22.5  4.8 4.5 **(*)
Neuropsychiatric Inventory (NPI, fraction with positive response):
Apathy subscore 0.000  0.0 0.616  0.5 13.3 **(*)
Disinhibition subscore 0.020  0.1 0.336  0.5 6.5 **(*)
Cambridge Behavioural Inventory (CBI-R, max 180) 5.2  5.6 66.7  35.2 18.2 **(*)
Kirby (difference) 0.005  0.04 0.019  0.1 1.6 NS
Behavioural tasks
Information Sampling Task (IST)
Probability of being correct Fixed 0.866  0.1 0.747  0.1 4.9 **(*)
Probability of being correct Decreasing 0.806  0.1 0.668  0.2 5.4 **(*)
Cued reinforcement reaction time (CRRT)
Reward-related speeding 43.4  90.9 196.3  739.1 2.4 *
Total errors 3.8  3.4 4.2  5.7 0.5 NS
Cambridge Gambling Task
Deliberation time 2240.0  767 7053.0  4449 1.4 **(*)
Risk adjustment 1.57  1.1 0.23  0.9 4.1 **(*)
Stop Signal Task (SST)
Stop signal reaction time (SSRT) 181.1  41.7 439.8  190.4 3.1 **(*)
Motor Go/NoGo Dprime 4.4  0.3 3.2  1.3 7.8 **(*)
Saccade Dprime 2.4  0.9 0.75  1.1 7.4 **(*)
Objective measures corrected for outliers  3 standard deviations (SD) of the mean. Independent samples t-test uncorrected for multiple comparisons are shown outside
parentheses: **P5 0.001, *P5 0.05. NS = not significant. Significance after Bonferroni correction is indicated by (*). Note that some measures are not independent, e.g. MMSE is a
component of the ACE-R, and NPI subscales are component of the total NPI score. CGT task data from 37 participants only.
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Table 3 Demographics, cognitive, functional and motor features by diagnosis
PSP CBS svPPA PPA bvFTD nvPPA Control
n 41 37 12 11 32 16 50
Age 72.9  8.5 69.7  7.8 71.1  4.1 73.1  4.9 64.0  7.3 71.6  9.1 70.6  6.5
Gender (M:F) 21:20 18:19 7:5 5:6 18:14 7:9 23:27
Duration (of symptoms) 4.5  3.4 4.1  2.3 5.7  2.9 4.1  2.2 4.9  3.0 2.0  2.0 NA
ACE-R (max. 100) 75.5  14.6 65.7  21.3 29.2  14.7 58.5  20.5 59.0  26.9 64.4  21.0 95.6  4.4
MMSE (max. 30) 25.0  4.8 22.0  6.6 11.8  8.7 21.0  5.1 21.4  7.6 23.0  6.3 29.3  1.2
FRS % score (max. 100) 40.9  25.1 31.4  23.3 20.9  14.6 66.3  28.4 26.8  18.0 63.7  28.4 92.1  10.8
FAB (max. 18) 10.5  4.0 10.0  4.4 9.4  3.8 10.0  4.4 9.4  5.3 9.2  4.4 16.8  1.2
PSP-RS (max. 100) 43.8  14.8 39.6  16.1 NA 5.3  4.7 16.1  10.0 8.4  6.2 NA
Akinesia, n (%) 35 27 2 2 22 31 0
Rigidity, n 35 27 0 1 6 1 0
Dystonia, n 25 24 0 0 2 0 0
Apraxia, n 22 33 2 8 8 11 0
Vertical gaze palsya, n 41 19 0 2 3 1 0
Postural instability/fallsb, n 41 24 0 1 7 2 0
Myoclonus, n 3 22 0 3 3 5 0
aOr slowing of vertical saccades; bor wheelchair dependence.
MMSE = Mini-Mental State Examination; FAB = Frontal Assessment Battery (FAB); PSP-RS = progressive supranuclear palsy rating scale.
Table 4 Rotated component matrix extracted from principal components analysis
Input variable Component structure
Component 1
Patient-rated
change
Component 2
Carer-rated
change:
Everyday
skills and
self-care
Component 3
Carer-rated
change:
Challenging
behaviours
Component 4
Impulsive
behaviours
Component 5
Impulsivity
self-report
Component 6
Goal-directed
decision-
making
Component 7
Stop Signal
Task
Component 8
Outcome
sensitivity
Eigenvalue 4.963 2.183 1.664 1.514 1.385 1.186 1.111 1.039
AES 1 0.832 0.069 0.121 0.151 0.078 0.003 0.041 0.069
BIS 1 0.735 0.086 0.083 0.221 0.080 0.003 0.095 0.052
BDI-T 0.756 0.345 0.100 0.073 0.158 0.097 0.026 0.030
MEI-T 0.837 0.232 0.061 0.109 0.023 0.034 0.142 0.007
SHAPS-T 0.688 0.147 0.281 0.067 0.276 0.136 0.068 0.075
AES 2 0.067 0.714 0.529 0.074 0.035 0.006 0.110 0.151
CBI 2 0.233 0.831 0.084 0.151 0.113 0.023 0.155 0.042
NPI-A 0.192 0.705 0.355 0.119 0.086 0.048 0.029 0.050
CBI 1 0.035 0.118 0.880 0.078 0.104 0.135 0.066 0.069
2NPI-D 0.135 0.083 0.825 0.008 0.017 0.039 0.017 0.092
IST 2 0.170 0.030 0.037 0.683 0.128 0.365 0.166 0.006
CRRT 1 0.007 0.014 0.006 0.658 0.013 0.104 0.390 0.109
Go/NoGo 0.259 0.135 0.113 0.642 0.130 0.042 0.259 0.007
Saccades 0.162 0.198 0.081 0.530 0.319 0.221 0.018 0.158
BIS 2 0.022 0.121 0.015 0.100 0.841 0.023 0.065 0.077
BISBAS 1 0.198 0.005 0.265 0.083 0.631 0.375 0.209 0.011
IST 1 0.188 0.204 0.080 0.177 0.013 0.556 0.311 0.052
CRRT 2 0.084 0.162 0.037 0.063 0.078 0.725 0.031 0.078
SST 1 0.183 0.109 0.021 0.044 0.167 0.087 0.793 0.030
BISBAS 2 0.068 0.090 0.088 0.042 0.242 0.179 0.141 0.804
Kirby 0.199 0.230 0.126 0.040 0.220 0.151 0.215 0.658
IST 3 0.255 0.382 0.198 0.167 0.335 0.007 0.283 0.001
Numbers (1, 2, 3) indicate the different components extracted from local PCA for AES, CBI, BIS, BIS/BAS, IST, SST, CRRT. Additional input variables included the total score for BDI,
MEI and SHAPS, NPI apathy and disinhibition subscores, Kirby difference value representing the difference in delayed discounting for low versus high rewards and Dprime
performance accuracy values for Go/NoGo tasks. High scores on Components 1–5 and 8 indicate worse performance, while low scores on Components 6 and 7 indicate worse
performance. Factor loadings 40.5 are highlighted in bold.
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extracted from the ﬁnal PCA (eigenvalues range: 1.039–
4.963). The rotated component matrix is provided in
Table 4. Note that assessments that are traditionally con-
sidered to be associated with apathy and impulsivity load
onto the same factors (e.g. AES and BIS), reﬂecting a high
positive correlation between components of apathy and
components of impulsivity. Inclusion of the Cambridge
Gambling task data from 37 participants did not alter the
factor structure, but in view of limited numbers this test
was removed from the main analyses.
Short names for components were given that encapsulate
their strongly weighted processes or tasks. However, please
refer to Table 4 for the weighting of each questionnaire or
test to each component. Component 1 reﬂects patient rat-
ings on questionnaires of apathy, impulsivity and related
changes termed ‘Patient-rated change’. Higher scores indi-
cate increased questionnaire endorsement of apathy, impul-
sivity, depression, anhedonia and low motivation.
Components 2 and 3 are associated with carer ratings of
patient change, with higher scores reﬂecting more abnormal
behaviours. Component 2, termed ‘Carer-rated change in
everyday skills and self-care’, is weighted to carer AES,
Cambridge Behavioural Inventory (CBI) (everyday skills,
self-care, sleep and motivation) and the Neuropsychiatric
Inventory (NPI) apathy subscore. The carer AES also
loads onto Component 3 ‘Carer-rated change in complex
behaviours’, in addition to remaining subscores of the CBI
(abnormal behaviour, eating habits, stereotypic behaviours)
and the NPI-disinhibition. The ﬁnal questionnaire-based
component, Component 5, is termed ‘Impulsivity self-
report’, to reﬂect increased ratings on BIS motor and cog-
nitive instability and BIS/BAS subscores.
Component 4 is associated with poor performance on
NoGo, information sampling and cued reinforcement tasks,
and termed ‘Impulsive behaviours’. Higher scores on
Component 6, termed ‘Goal-directed decision-making’, rep-
resent accurate performance on the information sampling
task and sensitivity to reward on the cued reinforcement
task. On Component 7, termed ‘SST performance’, high
scores reﬂect shorter stop-signal reaction times. Component
8, termed ‘Outcome sensitivity’, captures the incentive mo-
tivation elements of the Kirby and behavioural avoidance of
the BIS/BAS. Higher scores reﬂect reduced difference in tem-
poral discounting from small to large values of K on the
Kirby and increased behavioural avoidance.
The components were not speciﬁc to individual disease
groups, but reﬂected the transdiagnostic nature of apathy
and impulsivity. Figure 1 shows the distribution of compo-
nent scores in each of the six patient groups and controls.
ANOVAs conﬁrmed a signiﬁcant effect of group (and post
hoc t-tests comparing each patient group to controls) with
respect to Component 1 [F(6 192) = 6.35, P5 0.001: post
hoc control versus PSP P5 0.001, versus CBS P5 0.05];
Component 2 [F(6 192) = 17.1, P50.001: post hoc control
versus PSP P5 0.001, versus CBS P5 0.001, versus
bvFTD P5 0.001, versus svPPA P50.05]; Component 3
[F(6 192) = 19.9, P5 0.001: post hoc control versus bvFTD
P5 0.001, versus svPPA P5 0.001]; Component 4
[F(6 192) = 15.9, P5 0.001: post hoc control versus PSP
P5 0.001, versus CBS P5 0.001, versus PPA P5 0.001,
versus bvFTD P5 0.05, versus nvPPA P5 0.001];
Component 5 [F(6 192)5 1], Component 6
[F(6 192)51], Component 7 [F(6 192) = 1.7, ns]; and
Component 8 [F(6 192) = 2.0, P = 0.07].
Parametric Pearson’s correlation analyses (Table 5) re-
vealed that the patient rated change component
(Component 1) was related to disease severity (FRS) and
frontal dysfunction (FAB). Higher scores on Components
2–4 correlated with more severe disease (FRS), greater cog-
nitive decline (ACE-R, MMSE) and frontal dysfunction
(FAB). Component 2 was positively correlated with the
PSP-RS, reﬂecting greater PSP-like cognitive and motor im-
pairment. Poor performance on behavioural impulsivity
tasks (Component 4) was negatively correlated with PSP-
RS. Executive function, measured by ACE-R ﬂuency, cor-
related with Components 1–4 and 7.
Imaging results
The components of apathy and impulsivity were correlated
with distinct grey and white matter abnormalities, in corti-
cospinal, frontostriatal and subcortical systems. Figures 2
and 3 illustrate the distributions of signiﬁcant clusters
(multi-slice images for all signiﬁcant correlations are avail-
able as Supplementary material).
Signiﬁcant white matter correlates were identiﬁed for
Components 1, 2, 3 and 7 (Fig. 3) and grey matter correl-
ates for Components 2, 3, 4 and 7 (Fig. 2). Note that pa-
tients’ (Component 1) and carers’ (Components 2 and 3)
ratings were associated with distinct white matter correl-
ates. The patient ratings of Component 1 were related to
impairments in the corticospinal tracts, from the mid-
centrum semiovale, through corona radiata to the upper
brainstem. In contrast, the carer ratings correlated with
frontostriatal and brainstem systems. Speciﬁcally, carer-
rated change in everyday skills and self-care (Component
2) reﬂected localized brainstem white matter changes (me-
dulla, pons, and lower midbrain largely sparing the thal-
amus, and white matter deep to the middle frontal gyrus)
(Fig. 3 and Supplementary Fig. 4), with grey matter
changes extending from the caudate, putamen and thal-
amus into multiple cortical regions including medial and
lateral premotor and sensorimotor cortex, and scattered
foci in prefrontal, pariental and occipital cortex (Fig. 2
and Supplementary Fig. 5). Carer-rated behavioural
change (Component 3) was associated with widespread
but complementary changes in both grey and white
matter of the temporal pole, frontal pole, orbitofrontal
and medial frontal cortex and their connecting tracts
(Figs 2 and 3 and Supplementary Figs 6 and 7).
Performance on the motor/saccade response inhibition,
cued reinforcement and information sampling tasks
(Component 4) reﬂected grey matter change in multiple
regions including thalamus, lateral temporal cortex,
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posterior and dorsal-anterior cingulate cortex, and parieto-
occipital cortex (Fig. 2 and Supplementary Fig. 8).
Performance on the Stop-Signal task (Component 7) re-
ﬂected localized grey matter change in the right inferior
frontal region and anterior cingulate and white matter
change in the left frontal lobe (Figs 2, 3 and
Supplementary Figs 9 and 10).
Discussion
Our data provide four critical insights into apathy and im-
pulsivity, in addition to conﬁrming their multifactorial
nature. First, apathy and impulsivity are common in all
syndromes associated with FTLD, not only those that
Figure 1 Box plots of component scores (1–8) by diagnosis. Scale bars indicate post hoc Tukey tests for each group versus controls (thick:
P5 0.001, dotted: P5 0.05). Significant changes were observed for (A) PSP, CBS versus controls, (B) PSP, CBS, svPPA, bvFTD versus controls,
(C) svPPA, bvFTD versus controls, and (D) PSP, CBS, PPA, bvFTD, nvPPA versus controls. Box plots E–H showed no significant differences.
PC = principal component. *Extreme outlier (3  interquartile range, IQR), o = mild outlier (1.5  IQR).
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include apathy and impulsivity as diagnostic criteria.
Second, they are positively correlated, such that apathetic
individuals are also more likely to be impulsive. Third, the
components that reﬂect patients’ own ratings of apathy and
impulsivity are distinct from those based on carer observa-
tions and objective behavioural measures. Finally, the ana-
tomical networks associated with apathy and impulsivity in
our patients correspond with established networks for goal-
directed behaviour, social cognition, motor control and
vegetative functions. Speciﬁcally, carer ratings (AES, NPI,
CBI) reﬂect widespread disruption in frontostriatal, fronto-
temporal and brainstem systems required for motivation,
goal-directed behaviour and arousal, while patient ratings
(AES, BIS, SHAPS, BDI, MEI) correlated with changes in
corticospinal tracts, which we suggest reﬂects patients’
awareness of their motor deﬁcits despite lack of insight
into cognitive decline. Objective measures reﬂected loca-
lized changes in previously identiﬁed task-speciﬁc brain re-
gions (e.g. Stop-Signal task and right inferior frontal gyrus).
In this cross-sectional study, disease progression may
have obscured the phenotypic boundaries between syn-
dromes in comparison to their initial presentation
(Kertesz et al., 2005; Williams and Lees, 2009). This em-
phasizes the advantages of transitioning from a traditional
‘nominal’ diagnostic classiﬁcation (e.g. The Diagnostic and
Statistical Manual of Mental Disorders) to dimensional
approaches such as Research Domain Criteria with data-
driven methods as in our study. The recognition of apathy
and impulsivity across syndromes highlights the limitations
of diagnostic criteria, and means that symptomatic thera-
pies in one illness may help patients and carers affected by
another (Ye et al., 2014, 2015; Hughes et al., 2015).
Current criteria do not fully recognize the extent of behav-
ioural changes [e.g. nvPPA (Gorno-Tempini et al., 2011),
PSP (Litvan et al., 1996)], or emergence of behavioural
disorders with disease progression (e.g. svPPA) (Gorno-
Tempini et al., 2011). A clinical trial for such symptoms
would be most powerful if stratifying patients into ‘apath-
etic’ and/or ‘impulsive’ groups across the FTLD spectrum,
rather than diagnostic groups, which include patients with
and without the relevant symptoms.
This dimensional approach also provides a set of explicit
measures of disease severity, in terms of component
weights. When combined with the imaging analysis, it en-
ables better characterization of the neural systems under-
lying behaviours observed across the disorders. The
neuroimaging correlates of severity across the different
‘modes’ of apathy and impulsivity provide a principled
way to assess the beneﬁts of symptomatic and disease-mod-
ifying drugs on the neural systems that regulate different
behaviours, and do so using measurement tools that are
useful in the context of FTLD syndromes.
Before discussing the individual components, we highlight
two general features of the data. First, apathy and impul-
sivity were positively correlated. This contradicts theoretical
models in which impulsivity and apathy represent opposite
extremes of a simple spectrum of motivation. Some authors
have proposed that impulsivity represents a dopamine-de-
pendent spectrum of motivational or goal-directed control
(Zamboni et al., 2008; Ahearn et al., 2012; Sinha et al.,
2013) while apathy reﬂects an independent noradrenaline-
dependent spectrum of arousal and uncertainty (Remy
et al., 2005; Loued-khenissi and Preuschoff, 2015).
However, noradrenaline is also implicated in impulsivity
(Ye et al., 2015) and dopamine in apathy (Adam et al.,
2013; Sinha et al., 2013), indicating overlapping pharma-
cology. Although this study did not directly measure or
manipulate such neurotransmitters, our results are relevant
to the pharmacological analysis of apathy and impulsivity.
Speciﬁcally, the positive correlation we observe suggests
either that there is a common neurobiological basis for
apathy and impulsivity (Zhang et al., 2016), or that the
widespread pathology in FTLD syndromes leads to simul-
taneous deﬁcits in anatomically and pharmacologically dif-
ferent networks (Figs 2 and 3).
Second, the cognitive and neural components of apathy
and impulsivity differ according to the assessor: patient,
carer or experimentalist. The separation of patients’
(Components 1, 5 and 8) and carers’ (Components 2 and
3) ratings likely reﬂect patients’ lack of insight into disease-
related changes or their language difﬁculty with semantics
and grammar in questionnaires. Conversely, carers’ ratings
Table 5 Pearson’s correlations between the eight orthogonal components identified by principal components
analysis and the patients’ demographic, cognitive and severity ratings
Component Age FRS % ACE-R ACE-R fluency MMSE PSP-RS FAB
(PC1) Patient-rated change 0.050 0.271** 0.125 0.277** 0.085 0.134 0.258*
(PC2) Carer-rated change: everyday skills and self-care 0.047 0.658** 0.343** 0.335** 0.346** 0.550** 0.342**
(PC3) Care-rated change: challenging behaviours 0.172* 0.524** 0.357** 0.388** 0.335** 0.224 0.308**
(PC4) Impulsive behaviours 0.006 0.213* 0.354** 0.428** 0.293** 0.281* 0.397**
(PC5) Impulsivity self-report 0.106 0.041 0.087 0.03 0.109 0.078 0.001
(PC6) Goal-directed decision-making 0.055 0.017 0.104 0.037 0.077 0.074 0.023
(PC7) Stop Signal Task 0.037 0.080 0.172* 0.190* 0.170* 0.170 0.228*
(PC8) Outcome sensitivity 0.032 0.066 0.029 0.035 0.057 0.130 0.036
*P5 0.05; **P5 0.001 (uncorrected, approximating P5 0.05 corrected for multiple comparisons).
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may be biased by their own personal distress (Leroi et al.,
2012) or education about the illness. It is unlikely that pa-
tients lack insight into all aspects of their disease, but
clearly they differ from carers in terms of their awareness
of certain symptoms. Eliciting and quantifying behavioural
disorders through an interview with carers and/or question-
naires is a feature of both clinical practice and research but
may not quantify the differences between a patient’s own
symptoms (the usual target of treatment in medicine) and
the behavioural signs reported by carers (a major contribu-
tor to burden and patient risk). Our ﬁndings suggest that
clinical trials in syndromes associated with FTLD must dis-
tinguish whether treatments are for patients’ or carers’ well-
being. Furthermore, the subjective questionnaires did not
load onto the same components as objective behavioural
measures (Components 4, 6 and 7). The identiﬁcation of
homologous tasks in preclinical models and clinical popu-
lations can successfully facilitate translational therapeutics
(Kehagia et al., 2014; Hughes et al., 2015; Ye et al., 2015),
but may not readily apply to FTLD.
Although patients with FTD are said to lack insight,
Component 1 correlated with well-deﬁned and largely sym-
metric neural systems including corticospinal tracts. These
correlates differ from atrophy patterns identiﬁed from
voxel-based morphometry studies of PSP and CBD versus
controls (Cordato et al., 2005; Paviour et al., 2006; Josephs
et al., 2008b; Whitwell and Jack, 2010; Ghosh et al., 2012;
Wolpe et al., 2014), which highlight deﬁcits in the medial
frontal cortex, parietal lobe and brainstem. We speculate
that our result may reﬂect patients’ awareness of motor
deﬁcits, while insight into cognitive decline and behavioural
change remains limited.
In contrast to patient ratings, carer ratings of challenging
behaviours (Component 3) and vegetative features
(Component 2) correlated with frontostriatal and fronto-
temporal networks for motivational and arousal systems
Figure 2 Grey matter voxel-based morphology imaging results. Voxel-based morphology analysis revealed distinct neural grey matter
correlates for principal Components 2, 3, 4 and 7. Components 2–4 were negative, with higher component scores reflecting a loss of grey matter
in the relevant brain regions. Component 7 was positively correlated with the associated brain regions, with higher component scores reflecting
increased grey matter in the highlighted areas. Significant effects were identified using cluster-level statistics (FWEc P5 0.05, corrected for
multiple comparisons) above a height threshold of P5 0.005 (uncorrected). PC = principal component.
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(Chudasama and Robbins, 2006; Rushworth, 2008;
Berridge et al., 2010) and brainstem integrity. Both
Components 2 and 3 correlated with functional severity
(FRS) and cognitive decline (ACE-R, MMSE, FAB), sup-
porting the hypothesized associations between apathy, cog-
nition and functional decline (Starkstein et al., 2006).
Interestingly, both semantic and behavioural variants of
FTD were strongly weighted to Component 3. Although
svPPA is primarily diagnosed as a language disorder with
temporal lobe atrophy, the spread of pathology to orbito-
frontal systems and increasing behavioural change indicate
partial convergence of svPPA and bvFTD phenotypes
(Hodges and Patterson, 2007). The neural correlates of
Component 3 (Figs 2 and 3) suggest disrupted motivation
and reward processing circuitry with both apathy and im-
pulsivity, consistent with the regulation of reward, motiv-
ation and reinforcement by projections from the
orbitomedial prefrontal cortex and anterior cingulate to
ventral striatum (Dalley et al., 2011; Ahearn et al., 2012;
Eslinger et al., 2013). Carer ratings closely reﬂect changes
in these brain circuits previously implicated in apathetic
and impulsive behaviours (Levy and Dubois, 2006;
Zamboni et al., 2008; Sinha et al., 2013). Analogous
changes have been observed in many neurological and psy-
chiatric impulsivity disorders (Levy and Dubois, 2006;
Dalley et al., 2011; Ersche et al., 2011; Sinha et al., 2013).
The white matter correlates of Component 2 (everyday
skills and vegetative functions) were concentrated in the
brainstem (Fig. 3), with grey matter correlates extending
from the thalamus to posterior regions of cingulate and
parietal cortex (Fig. 2). These changes were most strongly
associated with PSP and CBS, consistent with previous re-
ports (Burrell et al., 2014). Degeneration of the brainstem
is proposed to affect the reticular activating system
that regulates wakefulness, attention and alertness.
Furthermore, sustained attention and oculomotor control
Figure 3 White matter voxel-based morphology imaging results. Voxel-based morphology analysis revealed distinct neural white
matter correlates for principal Components 1, 2, 3, and 7. Components 1–3 represent negative correlations, with higher component scores
reflecting a loss of white matter in the relevant brain regions. Component 7 was positively correlated with the associated brain regions, with
higher component scores reflecting increased white matter in the highlighted areas. Significant effects were identified using cluster-level statistics
(FWEc P5 0.05, corrected for multiple comparisons) above a height threshold of P5 0.005 (uncorrected).
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require functional integration of the brainstem, thalamus
and neocortical areas associated with this component,
and are particularly affected by PSP and CBS.
In other neuropsychiatric studies of impulsivity, including
addiction and Attention Deﬁcit Disorder, the BIS and BIS/
BAS questionnaires have been used to quantify individual
differences. These tests loaded onto Component 5. Similar
questions partly explain their presence in the same compo-
nent (e.g. BIS/BAS: ‘I often act on impulse’ versus BIS: ‘I act
on impulse’). But, the transdiagnostic plots (Fig. 1) suggest
that such responses do not readily distinguish patients af-
fected by FTLD.
The stop-signal task was weighted to Component 7.
Previous studies of health, Parkinson’s disease, ADHD
and ageing have consistently associated this task with the
integrity, activity and connectivity of the right inferior fron-
tal gyrus (Aron et al., 2003; Dalley et al., 2011), presup-
plementary area and subthalamic nucleus (Aron et al.,
2004), as well as noradrenergic (Kehagia et al., 2014; Ye
et al., 2015) and serotoninergic (Ye et al., 2014) function.
Higher scores on Component 7 correlated with increased
grey matter volumes in the right inferior frontal gyrus and
its connections to the striatum, providing further construct
validation of our dimensional approach.
The last and weakest component we termed ‘outcome sen-
sitivity’ due to its loadings from the Kirby and BIS/BAS’s BIS
subscore. The BIS subscore reﬂects a system for relaying cues
of punishment, non-reward and novelty, to regulate behav-
iour (Amodio et al., 2008). In the Kirby paradigm, steeper
discounting has been reported in drug addiction, schizophre-
nia and Parkinson’s disease (Housden et al., 2010). Group
comparisons (Fig. 1) and the lack of signiﬁcant anatomical
correlates are consistent with this component being a trait in
the general population, rather than a disease-speciﬁc deﬁcit.
Our study has methodological and interpretative limita-
tions. Although we aimed to assess the multifaceted con-
structs of apathy and impulsivity, some patients could not
perform the tasks, and the Cambridge Gambling Task
proved especially difﬁcult despite its successful application
in milder neuropsychiatric populations. The task was with-
drawn after 37 participants, but inclusion of these add-
itional data did not alter the factor structure signiﬁcantly,
and although patients were poor on the task, this effect was
captured by other tasks including the cued reinforcement
reaction time task (Cools et al., 2005). Interestingly, patho-
logical gambling is uncommon even in bvFTD, and the
impairment may arise partly from executive deﬁcits.
Some of the assessment tools were disease-speciﬁc, or
developed for a particular cohort, limiting their generaliza-
tion. For example, the FRS may not be directly applicable
to PSP and CBS. It could be therefore argued that one
should assess the neural correlates of performance separ-
ately within each diagnosis. However, reducing the analysis
to a multiplicity of tests of individual symptoms within
syndromes would have signiﬁcant drawbacks, not just in
terms of the severe loss of power to detect correlations in
small sub-cohorts. It would also belie the evidence of
clinical overlap and convergent symptomatology across
the separate diagnostic groups. Moreover, the use of
factor loadings for each component for each patient pro-
vides a more principled means to accommodate syndromic
variance, without bias or diagnostic circularity.
We sought to obtain the maximum information about
potential aspects of apathy and impulsivity, whilst bearing
in mind the tolerance and frailty of patients with FTLD-
associated disorders. However, our test battery is selective
and our conclusions only relate to the domains of cognition
and behaviour assessed. Some tasks that quantify apathy in
the healthy population are especially challenging in FTLD
disorders, because of sequential decisions, physical effort
and strong executive demands. For example, grip-force
effort (Bonnelle et al., 2015; Chong et al., 2015; Bouc
et al., 2016) might be confounded by the movement dis-
orders in several FTLD syndromes. Akinesia, depression
and executive deﬁcits may confound the assessment of
apathy.
Akinesia may readily be confused with apathy by obser-
vers. However, we suggest it is unlikely that the apathy we
identify is driven solely by akinesia, as akinesia across diag-
nostic groups does not mirror the severity of apathy
(Table 3 and Fig. 1). We indirectly measured motor fea-
tures, in terms of physical signs (including akinesia in the
PSPRS) and as reaction times in objective behavioural tests.
The correlations between the principal components and
PSPRS were very limited (Table 5). Depression can also
confound the assessment of apathy. Indeed, patient-rated
apathy, depression and anhedonia scores were positively
correlated (Component 1), despite distinctions between
the proposed underlying neurobiology of these complica-
tions (Levy et al., 1998). However, self-rated depression
symptom scores, as measured the BDI-II, are distinct to
the clinical disorder of depression that is primarily a
mood disorder. Apathy and depression may have
common symptoms, and both contribute to high scores
on a questionnaire such as the BDI-II, even as distinct
pathological entities. The role of executive function in
task performance must also be considered. Executive def-
icits are part of the diagnostic criteria for bvFTD, and sup-
portive criteria for PSP, and yet they are common in other
disorders associated with FTLD (Burrell et al., 2014).
However, a simple deﬁcit in executive function cannot ac-
count for the fractionation of apathy and impulsivity as
revealed by the PCA, nor the separate neural correlates of
each component. Rather, the separate impairments in be-
havioural control, inhibition, goal-directed behaviour and
appropriate planning of responses can be construed as a
part of the complex dysexecutive status resulting from
FTLD. Indeed, verbal ﬂuency, a marker of executive func-
tion (Perneczky et al., 2011), correlated with Components
1–4 and 7, in keeping with the association between execu-
tive functions and frontal lobe function (Shallice, 1988).
We suggest that executive dysfunction in our cohort is
best seen as encompassing—but not causing—the compo-
nents of apathy and impulsivity we observe.
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Voxel-based morphology changes in white matter should
be interpreted with caution (Smith et al., 2006), especially
where white matter correlates are observed in the absence
of grey matter correlates (e.g. Component 1). They may
reﬂect true white matter inﬂuences on complex behavioural
repertoires, but false positive correlations may arise from
normalization and mislocalization errors and the partial-
volume effects of smoothing. In contrast, the complemen-
tarity of white and grey matter correlates of Components 2
and 3 strengthens their interpretation. Voxel-based morph-
ology has been used extensively in the literature to examine
white matter volumes in PSP (Brenneis et al., 2004;
Cordato et al., 2005; Boxer et al., 2006; Josephs et al.,
2008b; Ghosh et al., 2012; Dutt et al., 2016), CBS/D
(Boxer et al., 2006; Josephs et al., 2008b; Whitwell and
Jack, 2010; Dutt et al., 2016) and FTD (Rohrer et al.,
2011). However, alternative methods are increasingly
common to study white matter changes in FTLD syn-
dromes, including diffusion-weighted imaging with voxel-
wise regions of interest or tract-based statistics (Whitwell
et al., 2010; Mahoney et al., 2014; Mandelli et al., 2014).
Despite differences in assumptions, confounds and sensitiv-
ity, there is generally consensus across these methods and
voxel-based morphology in the regional effects of FTLD
syndromes on white matter.
It is possible that our cohort is biased or unrepresentative
of the full spectrum of disorders associated with FTLD.
However, the study used multiple sources of referral in
community and specialist services, to reach all regional pa-
tients, and our attrition from case identiﬁcation (n = 204)
to neuropsychological assessment (n = 149) and MRI
(n = 70) included all disorders, while the imaged subset
was representative of the whole neuropsychological
cohort. Finally, we rely on clinicopathological correlations
and the current consensus criteria, acknowledging that for
some disorders (nvPPA, CBS and bvFTD) the clinicopatho-
logical correlations are weaker than others (svPPA, PSP).
In conclusion, we report that apathy and impulsivity are
common and overlapping consequences of FTLD.
Structural brain imaging revealed corticospinal tract im-
pairments in relation to patient ratings, in contrast to
carer ratings, which correlated with frontostriatal, fronto-
temporal and brainstem systems. Objective tasks and sub-
jective questionnaires used to measure these multifaceted
constructs do not correlate, warranting improved clinical
assessment tools to facilitate clinical trials. We argue that
a dimensional approach to investigate complex behavioural
changes is necessary and provides new insights into apathy
and impulsivity as well as reﬁning targets for novel drug
treatments.
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